- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07746713
A Study of JNJ-98768111 in Participants With Advanced Prostate Cancer
A Phase 1 Trial of JNJ-98768111, an Antibody Drug Conjugate (ADC) Targeting Human Kallikrein-2 (KLK2) for Advanced Prostate Cancer
The purpose of Part 1 of this study is to find out how safe JNJ-98768111 is and the most suitable dose (recommended phase 2 dose [RP2D]) regimen(s) of JNJ-98768111. The purpose of Part 2 of this study is to find out how safe JNJ-98768111 is at the RP2D regimen(s) in participants with advanced prostate cancer (cancer of the prostate, a male reproductive gland found below the bladder, which has spread extensively to other parts of the body).
연구 개요
연구 유형
등록 (추정된)
단계
- 1단계
연락처 및 위치
연구 연락처
- 이름: Study Contact
- 전화번호: 844-434-4210
- 이메일: Participate-In-This-Study1@its.jnj.com
연구 장소
-
-
Florida
-
Sarasota, Florida, 미국, 34232
- 모병
- Florida Cancer Specialists & Research Institute
-
-
Michigan
-
Grand Rapids, Michigan, 미국, 49546
- 모병
- Start Midwest
-
-
New York
-
New York, New York, 미국, 10016
- 모병
- Langone Health at NYC University, NYU School of Medicine
-
-
Utah
-
West Valley City, Utah, 미국, 84119
- 모병
- START Mountain Region
-
-
-
-
-
Haifa, 이스라엘, 3109601
- 모병
- Rambam Health Care Campus
-
Tel Aviv, 이스라엘, 64239
- 모병
- Sourasky Medical Center
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion criteria:
- a. Histologically confirmed adenocarcinoma of the prostate. Adenocarcinoma with small cell or neuroendocrine features is permitted. b. Measurable or evaluable disease (metastatic prostate cancer) based on computed tomography (CT), magnetic resonance imaging (MRI), or bone scan. Prior treatment with at least 1 prior novel androgen receptor (AR)-targeted therapy. c. Serum prostate-specific antigen (PSA) value greater than or equal to (>=) 2 nanograms per milliliters (ng/mL). d. Prior orchiectomy or medical castration; or, for participants who have not undergone orchiectomy, must be receiving ongoing androgen deprivation therapy (ADT) with a gonadotropin releasing hormone (GnRH) analog (agonist or antagonist) prior to the first dose of trial drug and must continue this therapy throughout the treatment phase; e. Castrate levels of serum testosterone as defined in the protocol, prior to the first dose of trial intervention; f. Progressive metastatic disease following their most recent line of therapy. Disease progression will be defined by at least one of the following: PSA progression, radiographic progression according to response evaluation criteria in solid tumors (RECIST v1.1), or progressive bone disease according to prostate cancer working group 3 (PCWG3) criteria
- Eastern cooperative oncology group (ECOG) performance status of 0 or 1
- Agree to all of the following during the trial and for 6 months after the last dose of trial drug: a. Use a highly effective method of contraception; b. Wear a condom when engaging in any activity that allows for passage of ejaculate to another person; c. Not to donate sperm or freeze for future use for the purpose of reproduction; d. Not plan to father a child. In addition, the participant should be advised of the benefit for a female partner to use a highly effective method of contraception
- Sign an informed consent form (ICF) indicating that the participant understands the purpose of, and procedures required for, the trial and is willing to participate in the trial
Exclusion criteria:
- Active central nervous system (CNS) involvement
- Toxicity related to prior anticancer therapy that has not returned to Grade less than or equal to (<=) 1 or baseline levels
- External beam radiation therapy to soft tissue lesions within 14 days prior to start of trial intervention
- History of clinically significant cardiovascular disease within 6 months prior to signing informed consent
- History of solid organ or bone marrow transplantation
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 순차적 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: JNJ-98768111
Participants in Part 1 of the study will receive escalating doses of JNJ-98768111 to identify the putative recommended phase 2 dose (pRP2D) regimen(s). Participants in Part 2 of the study will receive JNJ-98768111 at the pRP2D regimen(s) determined in Part 1. |
JNJ-98768111 will be administered intravenously. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number of Participants with Adverse Events (AEs)
기간: Up to approximately 2 years 7 months
|
An AE is any untoward medical occurrence in a clinical trial participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the treatment. |
Up to approximately 2 years 7 months
|
|
Part 1: Number of Participants with Dose-Limiting Toxicities (DLT)
기간: From first administration of trial intervention to the pre-dose assessment of the second cycle (up to approximately 2 years and 7 months)
|
High grade hematologic or non-hematologic toxicities with exceptions and/or toxicities leading to treatment discontinuation will be regarded as DLT. Other DLT criteria includes any related toxicity resulting in permanent treatment discontinuation or a delay in dose administration greater than (>)14 days and any death not clearly due to the underlying disease or non-trial intervention-related causes. |
From first administration of trial intervention to the pre-dose assessment of the second cycle (up to approximately 2 years and 7 months)
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Maximum Observed Concentration (Cmax) of JNJ-98768111
기간: Up to approximately 2 years 7 months
|
Cmax of JNJ-98768111 will be reported. |
Up to approximately 2 years 7 months
|
|
Trough Concentration (Ctrough) of JNJ-98768111
기간: Up to approximately 2 years 7 months
|
Ctrough of JNJ-98768111 will be reported. |
Up to approximately 2 years 7 months
|
|
Time to Maximum Observed Concentration (Tmax) of JNJ-98768111
기간: Up to approximately 2 years 7 months
|
Tmax of JNJ-98768111 will be reported. |
Up to approximately 2 years 7 months
|
|
Area Under the Concentration-Time Curve from Time 0 to End of Dosing Interval (AUC [0-tau]) of JNJ-98768111
기간: Up to approximately 2 years 7 months
|
AUC0-tau of JNJ-98768111 will be reported. |
Up to approximately 2 years 7 months
|
|
Accumulation Ratio of JNJ-98768111
기간: Up to approximately 2 years 7 months
|
Accumulation Ratio (RA) is calculated as area under the plasma concentration-time curve from time zero to 24 hours (AUC [0-24]) value at steady state divided by AUC (0-24) value after first dose. |
Up to approximately 2 years 7 months
|
|
Number of Participants With Anti-Drug Antibodies (ADAs) to JNJ-98768111
기간: Up to approximately 2 years 7 months
|
Number of participants with antibodies to JNJ-98768111 will be reported. |
Up to approximately 2 years 7 months
|
|
Objective Response Rate (ORR)
기간: Up to approximately 2 years 7 months
|
ORR is defined as the percentage of participants with measurable disease who have a partial response (PR) or better without evidence of bone progression according to prostate cancer working group 3 (PCWG3). |
Up to approximately 2 years 7 months
|
|
Radiographic Progression-Free Survival (rPFS)
기간: Up to approximately 2 years 7 months
|
rPFS is defined as the time from the date of first dose until the date of objective disease progression or death, whichever comes first. |
Up to approximately 2 years 7 months
|
|
Prostate-Specific Antigen (PSA) Response
기간: Up to approximately 2 years 7 months
|
PSA response rate is defined as the percentage of participants with a decline in PSA of 50% or more from baseline which is sustained for greater than or equal to (>=) 3 weeks. |
Up to approximately 2 years 7 months
|
|
Duration of Response (DOR)
기간: Up to approximately 2 years 7 months
|
DOR will be calculated among responders (PR or better) from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in the PCWG3, or death due to any cause, whichever occurs first. |
Up to approximately 2 years 7 months
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Janssen Research & Development LLC Clinical Trial, Janssen Research & Development, LLC
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 98768111PCR1001
- 2026-525894-37-00 (레지스트리 식별자: EUCT number)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .